Atlas Trials

Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1

Clinical trial NCT00784147 · COMPLETED

Trial details

NCT number
NCT00784147
Sponsor
TaiMed Biologics Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
HIV
Start date
2008-08-01
Primary completion
2011-04-01
Enrollment
113

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.